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ABSTRACT 
 
THE EFFECT OF INTACT PROTEIN FROM FOODS AND PHENYLALANINE 
FREE MEDICAL FOODS ON LARGE NEUTRAL AMINO ACIDS IN PATIENTS 
WITH PHENYLKETONURIA 
by 
Ann Berry 
 
Objective: The primary aim of this retrospective cohort study was to determine the association 
between the source of dietary protein intake and the sum of plasma concentration of large neutral 
amino acids (LNAA) in patients with Phenylketonuria (PKU).  A secondary aim of the study was 
to examine the effect of dietary compliance on plasma concentration of LNAA. Methods: The 
analysis included combined participant data from two previous studies conducted at the Emory 
University School of Medicine. Subjects are males (n=34) and females (n=43) with PKU ages 4-
50 years. A Student t-test was used to compare total combined plasma LNAA (excluding 
tryptophan and phenylalanine) by dietary compliance status (alpha=0.05). Correlation statistics 
were used to determine the association between the ratio of reported intact food protein to 
medical food protein on plasma levels of LNAA.  Multiple regression analysis was used to 
examine the contribution of intact protein to medical food protein ratio and other variables to 
plasma LNAA.  Results: The median ratio of intact protein to medical food protein reported was 
0.354 (IQR: 0.188, 0.914).  Median percent of PHE intake over the PHE intake recommendation 
was 31.64 (Interquartile range [IQR]; 7.44, 104.98).  Plasma concentration of LNAA did not 
differ significantly between those with plasma PHE levels within the therapeutic range <360 
μmol/L (compliant; 611.7 μmol/L [n=19]) vs levels above the therapeutic range (non-compliant; 
595.3 μmol/L [n=47]); p=0.613).  There was an inverse marginal correlation between the ratio of 
intact protein to medical food protein and plasma concentration of LNAA for those who were 
compliant (r = -0.436, r = 0.1) although the association was not statistically significant (p=0.08). 
  
No correlation was found for patients who were non-compliant. Regression analysis revealed that 
plasma concentration of LNAA was not significantly affected by the ratio of intact protein to 
medical food protein ratio, age, or gender.  Conclusions:  Although not statistically significant, a 
negative trend was observed between plasma LNAA concentration and the intact protein to 
medical food protein ratio in patients compliant with the PHE prescription. This suggests that the 
ratio of intact dietary protein to protein coming from medical food, as reported by patient diet 
records, may promote increased plasma LNAA levels in the effective treatment of PKU. The 
majority of the sample (74%) were non-compliant with diet based on plasma PHE levels.  Future 
studies are needed to determine the consequences of non-compliance by decreased intake of 
medical food protein or increased intake of intact protein on plasma LNAA concentration and 
downstream health effects. 
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CHAPTER I 
 
THE EFFECT OF INTACT PROTEIN FROM FOODS AND PHENYLALANINE 
FREE MEDICAL FOODS ON LARGE NEUTRAL AMINO ACIDS IN PATIENTS 
WITH PHENYLKETONURIA 
INTRODUCTION 
 Phenylketonuria (PKU) is a rare metabolic disorder in which the body does not 
utilize the essential amino acid (EAA) phenylalanine (PHE).  The condition affects up to 
1 in 20,000 people in the United States.1 Phenylketonuria is an autosomal recessive 
genetic disorder in which the enzyme, phenylalanine hydroxylase (PAH), produced in the 
liver, is deficient.1  The lack in activity of PAH causes PHE to build up in the blood and 
body tissues which is toxic to the central nervous system, most notably the brain.2  If 
untreated at birth, infants with PKU can suffer from neurological complications including 
intelligence quotient loss, memory loss, problems with concentration, mood alterations, 
and in serious cases severe mental retardation.1  However, when PKU is detected at birth 
through Newborn Screening and a proper therapeutic diet is followed, the child can live a 
normal healthy life.1   
 Phenylketonuria is treated with a strict low PHE diet and a synthetic, PHE free, 
amino acid-based nutritional formula that serves as the major dietary protein source.1,2  
The goal of the diet is to keep patient blood PHE levels in between 120-360 μmol/L level 
which is needed for normal development and throughout the lifespan.1  National dietary 
guidelines for patients with PKU are available3, but whether patients with PKU are 
meeting these guidelines is not known. PHE intake is necessary for the body to make 
tyrosine which then is responsible for making proteins and brain chemicals such as L-
 
 
 
 
2 
dopa, epinephrine, norepinephrine, and thyroid hormones.4 Therefore, some PHE must be 
consumed from the diet, but high protein foods such as poultry, eggs, fish, meat, cheese, 
milk, and legumes should be avoided.  As a result, dietary intake of other EAAs is 
limited.1 These other EAAs include histidine, isoleucine, leucine, lysine, methionine, 
threonine, tryptophan, and valine.5 Essential amino acids are critical nutrients in the diet 
because they cannot be synthesized by the body.  The supplemental formulas provided to 
patients with PKU are meant to provide these essential amino acids without PHE.  
However, it is unknown whether these formulas, along with a low protein diet provide the 
dietary requirements for essential amino acids.   
 Large neutral amino acid (LNAA) levels may also play an important role in the 
treatment of PKU.  Large neutral amino acids include the EAAs histidine, isoleucine, 
leucine, methionine, threonine, tryptophan, phenylalanine and valine as well as the non-
essential amino acid tyrosine.6  Consumption of LNAAs will increase levels of these 
amino acids in the bloodstream and may reduce blood PHE levels and the concentration 
of PHE in the brain.6 Adequate concentrations of LNAAs are important as they have a 
common transport system with PHE at the blood-gut barrier as well as the blood-brain 
barrier.6 All LNAAs compete for similar carrier proteins at these locations and it is 
believed that higher concentrations of LNAAs may inhibit transporters from taking up 
PHE at these sites.6 However, it is unknown whether there is an association between 
dietary intact protein intake or the protein composition of medical formula with plasma 
levels of LNAAs in those with PKU. 
PAH differs between patients with PKU resulting in varied tolerance to foods 
containing PHE.7    Patients with mild PHE restrictions can consume more high protein 
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foods and may be getting more essential amino acids through the diet, including LNAA.  
The goal of this research study is to describe the dietary intake of individuals with PKU 
and assess whether they are receiving the recommended intake of energy and total protein 
intake along with adequate LNAA in the diet. The sample population includes patients 
who participated in two studies conducted by Rani H. Singh, PhD RD and Teresa 
Douglas, PhD at the Emory University School of Medicine.  The first study included 
patients (>4 years of age) with PAH deficiency (Sapropterin Study).  The second study 
included female patients ages 12 and older with PAH deficiency who attended the Emory 
University Metabolic Nutrition Program’s Metabolic Camp in the summer of 2016.  We 
set out to determine intake adequacy by analyzing patient diet records of food and 
formula intake and examining their serum levels of large neutral amino acids (LNAA) 
including valine, isoleucine, methionine, leucine, tyrosine, histidine, threonine, and 
tryptophan.6 Associations were investigated for enteral intake and plasma concentrations 
to determine if the protein source as well as compliance to the therapeutic diet has a 
relationship on those with PAH deficiency.   
The purpose of this study is to determine whether people with PKU are meeting 
recommended nutrition intake guidelines and to examine the effect that amino acid 
supplements and intact food sources of protein have on plasma LNAA levels in patients 
with PKU. These data will be used to determine whether further intervention is necessary 
to meet total energy and dietary protein needs as well as assess the effect of intake of 
LNAAs on plasma concentrations. 
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Specific Aim 1: Compare energy and total dietary protein from both intact and medical 
foods to energy and protein intake recommendations in the Nutrition Management 
Guidelines for Phenylketonuria (PKU, PAH deficiency).  
 Research Hypothesis 1A: Protein and energy intake will be higher than 
recommended intake guidelines for individuals with PAH deficiency. 
 Null Hypothesis 1: Protein and energy intake of individuals with PAH deficiency 
will meet not meet recommended intake guidelines. 
 
Specific Aim 2: To determine the association between enteral intake and plasma 
concentrations of LNAAs as affected by dietary compliance and protein source in 
individuals with PAH deficiency. 
 Research Hypothesis 2A: Individuals with PAH deficiency who are strictly 
adherent to therapeutic diet will have a higher plasma concentration of LNAA than those 
who are less compliant. 
 Null Hypothesis 2A: Dietary and plasma concentration of LNAA will not differ 
by dietary compliance in children with PKU. 
 Research Hypothesis 2B: Dietary ratio of intact protein to medical food protein as 
sources of LNAA will predict plasma concentrations of LNAA in patients with PAH 
deficiency.   
 Null Hypothesis 2B: Large neutral amino acid dietary intake does not affect 
plasma concentration of LNAA regardless of dietary source.
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CHAPTER II 
LITERATURE REVIEW 
Phenylketonuria and Dietary Treatment 
 Phenylketonuria is an inborn error of metabolism in which the activity of the 
enzyme phenylalanine hydroxylase (PAH) is deficient (Figure 1).8  Phenylalanine 
hydroxylase converts PHE into tyrosine which then produces brain chemicals such as L-
dopa, epinephrine, norepinephrine, and thyroid hormone.4  The lack of PAH activity in 
those with PKU leads to PHE accumulation in the blood and can cause symptoms such as 
mental retardation, physical disability, and concentration difficulties.9  In order to prevent 
these symptoms, dietary treatment is put into effect immediately upon diagnosis via 
Newborn Screening.  Treatment includes a lifelong low PHE diet, including foods 
naturally low in protein such as fruits and vegetables, as well as specially formulated 
foods specifically made for those with PKU. A PHE-free amino acid formula (or medical 
food) is also consumed daily.  Those with PKU are allotted an individualized amount of 
PHE each day depending on his/her PAH activity affecting PHE tolerance. The amino 
acid formula is prescribed according to how much natural protein the patient can 
consume as well as the age, height and weight of the individual.  The amino acid mixture 
provides the patient with the daily requirement of protein as well as vitamins, minerals, 
and trace elements that may be under consumed in the restricted diet.
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Figure 1.  Metabolism of Phenylalanine Hydroxylase (PAH) in Phenylketonuria (PKU).8 
 
Nutrient Requirements for People with Phenylketonuria 
 The latest nutrition management guidelines for PKU were released in 2016.3 The 
guidelines give specific nutrient requirements for clinicians treating patients with PKU.  
The first recommendation is to determine the amount of intact protein needed to provide 
a patient’s recommended intake of PHE (Table 1).  Adequate protein is necessary to 
promote anabolism and to maintain proper blood concentrations of PHE. The second 
recommendation is to determine total protein intake, including intact protein and protein 
from the amino acid mixture prescribed.  The recommended total protein intake for 
people with PKU includes 50% more protein than the Dietary Reference Intakes (DRI) 
for infants birth to age 4 years (1.5 g/kg/day for infants, 1.1 g/kg/day for 1-3 years) and 
20-40% more protein than the DRI for those older than 4 years of age (0.95 g/kg/day for 
4 – 13 years, 0.85 g/kg/day for 14 – 18 years) .3  The L- amino acids that are in medical 
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formula are oxidized more quickly and therefore lead to an increased protein 
recommendation.3 Thirdly, the amino acid tyrosine should be supplemented if blood 
tyrosine levels are consistently low.3  Finally, those with PKU also should meet the DRI 
values for other macronutrients, micronutrients, and energy.3  The goal of these 
recommendations is for individuals with PKU to maintain a blood PHE level of 120-360 
μmol/L while meeting all of their nutritional needs.3 
 
Table 1.  Guidelines for Energy, Phenylalanine, Tyrosine and Protein for Individuals with 
PKU*   
Age Energy 
(kcals/kg/day)  
PHE (mg/day) TYR (mg/day) Protein 
(g/kg/day) 
Infant to <4 years 
0 to <3 months 102 130-430 1100-1300 2.5-3.0 
3 to <6 months 82 135-400 1400-2100 2.0-3.0 
6 to 9 months 80 145-370 2500-3000 2.0-2.5 
9 to <12 months 80 135-330 2800-3500 2.0-2.5 
1 to <4 years ** 200-320 2800-3500 1.5-2.1 
After early childhood 
4 to 5 years 65-70  
 
 
 
 
 
200-1100 
 
 
 
 
 
 
4000-6000 
 
 
 
 
 
 
120-140% DRI 
for age 
6 to 7 years 61-64 
8 years 59 
9 to 11 years 42-49 
12 to 13 years 40-44 
14 to 16 years 33-39 
17 to 18 years 31-37 
PHE – phenylalanine, TYR – tyrosine, PKU – phenylketonuria 
Kcal – kilocalories, kg – kilograms, mg – milligrams, g - grams 
*Adapted from Singh et al. (2016) and Texas Children’s Hospital Pediatric Nutrition 
Reference Guide3,10 
**Energy requirements: 12 to <36 months (82 kcal/kg/day); 3 years (82-85 kcal/kg/day) 
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Multiple amino acid mixtures are available on the market (Table 2).  The clinician and 
the patient can determine which product would be most applicable to the patient’s needs.  
The amino acid mixture should be selected based on the recommended nutrient intake for 
the patient and considering adherence by the patient.  If an incomplete amino acid 
mixture is chosen, a vitamin, mineral, energy and/or fat supplement should be 
incorporated in appropriate if adequate amounts are not available in the diet.3 Medical 
formula should be consumed throughout the day in order to maintain consistent blood 
PHE levels.3 
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Table 2. Enteral medical products for Infants, Children, Adolescents and Adults with 
PKU 
Composition
 
Amino acids, 
fat, 
carbohydrate, 
vitamins, and 
minerals 
Amino acids, 
carbohydrate, 
vitamins, and 
minerals 
Amino 
acids 
Glyco-
macropeptide 
Large 
neutral 
amino 
acids 
Nutrient 
profile 
Most complete Most vitamins 
and minerals, 
no fat 
Few or no 
vitamins and 
minerals and 
no fat 
Variable 
depending on 
product, 
contains PHE 
Variable 
depending 
on product 
Energy/ 
protein ratio 
(kcal/ protein) 
High to 
medium 
Medium to low Low Variable Low 
Forms Powder Powder, ready-
to-drink 
Powder, 
capsules, 
tablets 
Powder, ready 
–to-drink, bars, 
pudding 
Powder, 
tablets 
Products 
designed for 
infants 
Periflex Infant, 
Phenex-1, 
Phenyl-Free 1 
None None None None 
Products 
designed for 
children 
Periflex 
Junior, 
Phenex-2, 
PhenylAde 
Essential, 
Phenyl-Free 2 
Lophlex, 
PhenylAde 40, 
PKU Coolers, 
PKU Gel, 
Maxamaid XP 
None Bettermilk <12, 
Complete Bars 
<12, Restore 
Lanaflex 
Products 
designed for 
adolescents 
and adults 
Periflex 
Advance, 
Phenex-2, 
PhenylAde 
Essential, 
Phenyl-Free 2, 
Phenyl-Free 
2HP 
Lophlex LQ, 
PhenylAde 
RTD, 
PhenylAde 40, 
PhenylAde 60, 
PKU Coolers, 
Maxamum XP 
PhenylAde 
Amino Acid 
Blend and 
Amino Acid 
Blend MTE, 
Phlexy-10 
Bettermilk 12+, 
Complete bars, 
Restore, 
Restore Lite, 
Swirl 
PheBloc 
 
*Adapted from Singh et al. (2014)11 
 
The Therapeutic Diet and Essential Amino Acid Levels 
Several studies have been conducted to determine whether a restricted diet results 
in nutrient deficiencies in patients with PKU.  There is also research on the effects of 
glycomacropeptide (GMP) based medical formulas, a low PHE whey protein, compared 
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to traditional synthetic amino acid formulas. However, there is limited research on the 
effect of the level of PHE restriction, the type of amino acid mixture used, and how these 
variables affect plasma LNAA concentrations.   
Research has been conducted on the effect of adding LNAAs in the PHE free 
amino acid mixture on plasma amino acid levels.  In a study by Schindeler et al. (2007), 
the researchers found that blood isoleucine, leucine, threonine, tyrosine, valine, lysine, 
and histidine levels were all highest when the subjects were receiving the LNAAs with 
their amino acid mixture. 12 They also reported that methionine was higher in the phase in 
which patients were taking the LNAAs but not when they consumed their standard amino 
acid formula without LNAAs.  They observed this in patients who were consuming a 
formula that was low in methionine vs. a 267% increase in methionine and a 127% 
increase in histidine with LNAA supplementation.  These results show that formula 
composition and intake may have an effect on LNAA amino acid levels.   
Essential amino acid supplementation has been shown to be vital in the treatment 
of PKU.  However, the quantity and quality prescribed can differ among metabolic 
clinics.  A study conducted in Europe assessed how different clinics prescribe the amount 
of protein to be received for each PKU patient.13  The researchers determined that only 
46% of the participating centers calculated an “inefficiency factor” and allowed for a 
mean 20% of additional protein to make sure that the patient was receiving adequate 
protein and remained in positive nitrogen balance.   They found that 64% of centers 
recommended giving the amino acid mixture three times a day and 17% recommended 
four times a day. 13  Most centers recommended L-amino acid formula with added 
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vitamins and minerals with only three centers recommending GMP products and 17% 
recommending LNAA supplementation. 13   
 Recently, GMP has been introduced as an alternate PKU low PHE amino acid 
source. GMP is a 64-amino acid glycosylated peptide that is a byproduct of cheese 
production that remains in the whey portion.14 Glycomacropeptide does not contain any 
aromatic amino acids such as PHE.  However, GMP can be contaminated with other 
whey proteins and provide some PHE when used in commercial products.  
Glycomacropeptide is two to three times higher in isoleucine, threonine, and valine and 
does not contain all amino acids to be a complete source of protein for patients with 
PKU.14  Studies have shown that a low protein diet with GMP provides 70% of intact 
protein intake from the GMP products as well as from fruits and vegetables vs. a low 
protein diet with synthetic amino acid mixture that provides only 20% of intact protein 
from fruits and vegetables.14  Glycomacropeptide has been shown to increase the total 
amino acids in plasma when compared to synthetic amino acid supplements due to a 
slower transit time in the digestive system with intact proteins vs. synthetic proteins.14,15  
It has also been proven to increase the LNAA isoleucine and threonine and this has 
shown a reduced level of plasma PHE concentration in mice studies.15  Further research 
is needed in order to determine what supplementation products are best for providing 
total repletion of the vital nutrients required by a patient with PKU when following a 
strict low PHE diet.   
Large neutral amino acids compete for the same carrier sites at the blood brain 
barrier as PHE, therefore, inhibiting PHE passage into the brain when levels of LNAAs 
are high.3 Limited research on LNAA supplementation has shown improvements in blood 
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tyrosine levels and decreases in brain PHE using Magnetic Resonance Spectroscopy.3,16  
Best practices for LNAA supplementation have not yet been determined.  However, the 
majority of recommendations support the use of 20-30% of the DRI protein requirement 
(0.8 g/kg/day) from LNAAs, and the remaining 70-80% from intact dietary protein.3 
LNAA supplementation has shown to have a role in PKU treatment.  However, it is still 
unknown whether there is a correlation between intact dietary protein and type of medical 
formula with plasma LNAA levels.  
 A study conducted by Rohde et al. (2014) reported that patients with PKU may be 
at greater risk for micronutrient and essential amino acid deficiencies. This study 
evaluated 3-day diet records that included intact dietary intake and amino acid medical 
food.10 Due to the higher intake of natural protein, this study aimed to identify whether or 
not dietary intake without medical food placed the patients at greater risk for nutrient 
deficiencies. The study included two groups, patients who received medical food vs. 
those who did not.  The researchers reported that total protein intake was not significantly 
different between the groups.10  However, PHE intake was significantly lower (P=0.006) 
in the group that received medical food. 10 No essential amino acid deficit was found in 
either group.10 
 Another study by Schulpis et al. (2011) showed differences in serum amino acid 
levels after subdividing patients with PKU into two groups depending on their mean 
annual PHE blood concentrations.8  Both groups received the same amino acid 
supplemental formula (PKU2Prima) which was enriched with vitamins and trace 
elements but contained no PHE.8  Group A was defined as the “relaxed diet group” who 
had not had good control over their serum PHE levels.8  Group B was defined as those 
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patients who “strictly adhered to the diet”.  The researchers reported no statistically 
significant difference in the total protein intake in the two groups.8  However, the analysis 
did not include essential amino acid intake.    
 Pimental et al. (2014) evaluated the protein value in 16 low PHE recipes 
formulated for patients with PKU.17  The researchers found that all of these products had 
low protein content and therefore did not meet essential amino acid requirements. The 
results of this study pointed out that amino acids are not equally distributed among 
protein sources. High positive correlations were found between total protein and PHE as 
well as other amino acids such as leucine, methionine, isoleucine, proline, histidine, and 
glycine (R=0.9842, 0.9811, 0.9464, 0.9275, and 0.9132, respectively). 17  These results 
reveal that by restricting PHE in the diet, some essential amino acids are not provided in 
sufficient quantity without proper intake of  a PHE free amino acid formula.   
 The literature review reveals that adequate energy and protein intake, as well as 
LNAA concentrations, are important in the monitoring and treatment of PKU. The aims 
of this study are to examine the intake of energy and protein and LNAA plasma 
concentrations in the participants at Emory University School of Medicine to evaluate 
further interventions needed in the treatment of PKU. 
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CHAPTER III 
 
MANUSCRIPT IN STYLE OF MOLECULAR GENETICS AND METABOLISM 
 
Introduction 
 Phenylketonuria (PKU) is a rare metabolic disorder in which the body does not 
utilize the essential amino acid (EAA) phenylalanine (PHE).1 Phenylketonuria is an 
autosomal recessive genetic disorder in which the enzyme, phenylalanine hydroxylase 
(PAH), produced in the liver, is deficient.1  The lack in activity of PAH causes PHE to 
build up in the blood and body tissues which is toxic to the central nervous system, most 
notably the brain.2 Phenylketonuria is traditionally treated with a strict low PHE diet and 
a synthetic, PHE free, amino acid-based nutritional formula that serves as the major 
dietary protein source.1,2  The goal of the diet is to keep plasma blood PHE between 120-
360 μmol/L, the level which is needed for normal development and cognitive function.1   
 Plasma large neutral amino acid (LNAA) concentration may also play an 
important role in the treatment of PKU.  Large neutral amino acids include the EAAs 
histidine, isoleucine, leucine, methionine, threonine, tryptophan, phenylalanine and valine 
as well as the non-essential amino acid tyrosine.3  Consumption of LNAAs will increase 
levels of these amino acids in the bloodstream and may reduce blood PHE levels and the 
concentration of PHE in the brain.3 Adequate concentrations of LNAAs are important as 
they have a common transport system with PHE at the blood-gut barrier as well as the 
blood-brain barrier.3 All LNAAs compete for similar carrier proteins at these locations 
and it is believed that higher concentrations of LNAAs may inhibit transporters from 
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taking up PHE at these sites.3 However, it is unknown whether there is an association 
between dietary intact protein intake or the protein composition of medical formula with 
plasma levels of LNAAs in those with PKU. 
 The purpose of this study is to examine the effect that different amino acid 
supplements and intact food sources of protein have on plasma LNAA levels in patients 
with PKU. We aim to compare energy and total dietary protein from both intact and 
medical foods to energy and protein intake recommendations in the Nutrition 
Management Guidelines for PKU. In addition, we aim to determine the association 
between enteral intake and plasma concentrations of LNAAs as affected by dietary 
compliance and protein source in individuals with PAH deficiency.  We hypothesize that 
protein and energy intake will be higher than recommended intake guidelines for 
individuals with PAH deficiency, that individuals with PAH deficiency who are strictly 
adherent to therapeutic diet will have a higher plasma concentration of LNAAs than those 
who are less compliant, and that the dietary ratio of intact protein to medical food protein 
as sources of LNAAs will predict plasma concentrations of LNAAs in patients with PAH 
deficiency.  These data will be used to determine whether further intervention is 
necessary to meet total energy and dietary protein needs as well as assess the effect of 
intake of LNAAs on plasma concentrations.   
 
Methods 
Study Population 
 The study sample included participants from two previous studies conducted by 
Rani H. Singh PhD, RD and Teresa Douglas, PhD at Emory University School of 
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Medicine. Part of the sample consisted of females with PKU ages 12 years and older who 
participated in the Emory Metabolic Camp in the summer of 2016.  The other study 
population consistent of males and females ages 5 and older from the Sapropterin 
(Kuvan) Study. All patients had been diagnosed with PKU through the Newborn 
Screening Protocol.  Patients with other dietary restrictions such as gluten or lactose 
intolerance and those with an existing pregnancy were excluded. 
 
Study Design 
 The project is a secondary retrospective cohort study.  Data previously collected 
as part of the Institutional Review Board (IRB) approved Emory Metabolic Camp 
protocol and the Sapropterin (Kuvan) Study protocol by Dr. Rani H. Singh and Dr. 
Teresa Douglas in the Department of Human Genetics, Emory University School of 
Medicine was used.  Variables included demographic characteristics (age in years, 
gender, and race), anthropometrics (weight in kg, height in cm, head circumference in 
cm, calculated BMI), nutrient intake from dietary food records, PAH status, and 
determinants of dietary compliance.  Each patient was assigned a random identification 
number and no personal identifiers were collected.  Ethics approval for this secondary 
analysis study was received from the Georgia State University IRB. 
 
Anthropometric Measures 
Weight (kilograms) was measured with a standing scale.  Height (centimeters) was 
determined using a stadiometer. Body mass index (BMI) was calculated using the 
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following equation weight (kilograms) / height (meters)2.  All measures were done by 
trained research staff.4  
 
Dietary Assessment 
All participants at the Emory Metabolic Camp and at the baseline visit for the 
Sapropterin Study completed a 3-day food record prior to their study visit.  A Registered 
Dietitian from Emory University analyzed each individual’s 3- day food record for 
nutrient intake using Nutrition Data System for Research (NDSR; Nutrition Coordinating 
Center, University of Minnesota, 2016).4 In the current study, dietary compliance was 
determined by blood PHE levels within the normal range (<360 μmol/L), dietary intake 
within recommended guidelines as reported on the 3-day food record, and consumption 
of the amino acid medical food prescribed as reported on the 3-day food record.4 
Phenylalanine was also not included in order to identify the relationship between the 
beneficial effects of other plasma LNAAs on compliant PHE levels as well as the intact 
dietary protein to medical formula protein ratio. 
 
Blood Sampling 
Green top tubes were used for blood sampling.  Plasma amino acids were 
analyzed using quantitative ion exchange chromatography at Emory Genetics Laboratory 
and standardized per liter of creatinine.17 LNAA concentration was calculated using the 
sum of the individual plasma LNAAs, a method previously used to find benefits of 
LNAA, including leucine, valine, isoleucine, histidine, methionine, threonine, and 
tyrosine values.5  Tryptophan was not included in the calculation as the measure is not 
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routinely determined and the value was not available for half of the population (n=39). 
To determine the severity of PAH deficiency based on genotype, venous blood samples 
were obtained in Sapropterin Study participants and dried blood spots collected on filter 
paper were obtained in Metabolic Camp participants. Polymerase chain reaction was 
conducted at the Emory Genetics Laboratory to extract DNA from the blood and filter 
paper samples.  The severity of PAH deficiency was categorized as classical/severe 
(assigned value = 2) or mild/moderate (assigned value >2) using a previously determined 
method of AV sum.4,6 
 
Statistical Analysis 
 Frequency statistics was used to describe the demographic, anthropometric, 
nutrient intake and clinical characteristics of the population.  Normality testing was 
conducted on all continuous variables to determine whether parametric or nonparametric 
statistics should be used.  Descriptive statistics were used to compare dietary intake of the 
participants with intake recommendations. A student t-test was used to compare LNAA 
concentration by dietary compliance status. Spearman’s rho correlation statistics were 
used to determine the association between the intact protein to medical food protein ratio 
and plasma concentration of LNAA.  Multiple regression analysis was used to examine 
the contribution of the intact protein to medical food protein ratio and other variables, 
such as age and gender, to plasma concentration of LNAA.  All statistical analysis were 
conducted using SPSS (version 23.0, SPSS Inc. Chicago, IL).  A P-value of <0.05 was 
considered statistically significant. 
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Results 
Demographic and Anthropometric Characteristics 
The study population included 77 participants (44% male) with a mean age of 18.4 + 10.9 
years (range, 4 to 50 years).  The majority of the population were participants of the 
Kuvan study (n=62) while the remaining participants attended the Emory Metabolic 
Camp in the summer of 2016. The median weight of the population was 56.3 kg 
(Interquartile range [IQR]; 36.6, 79.2), the median height was 158.2 cm (IQR; 142.1, 
165.3), and the median BMI was 22.1 kg/m2 (IQR; 17.8, 28.4).  
 
Nutrient Intake and Dietary Compliance 
Median fat, carbohydrate, and protein intakes were 47.9 grams (IQR; 35.9, 64.5), 235.2 
grams (IQR; 203.5, 286.3), and 58.2 grams (IQR; 47.8, 70.1), respectively. Median 
energy intake was 31.588 kcal/kg (IQR; 9.1- 92.1) and median protein intake was 1.108 
g/kg (IQR; 0.1- 3). Median dietary protein intake was 14.4 grams (IQR; 9.5, 27.2) and 
medical formula protein intake was 39.3 grams (IQR; 27, 53.4) grams.  A comparison of 
these intake values to the Nutrition Management Guidelines for PKU are shown in Table 
3. Median intake of individual amino acids are shown in Table 4. Medical Formula type 
was differentiated based on PHE content. The majority of participants (n=64) were 
consuming a PHE-free formula while 4 participants were consuming a PHE-containing 
product which would affect total plasma LNAA concentration. Two participants were 
taking a tyrosine supplement which would also affect total plasma LNAA concentration. 
The median ratio of intact protein to medical food protein reported was 0.354 (IQR; 
0.188, 0.914).  The median percent of PHE intake over the PHE intake recommendation 
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was 31.64 (IQR; 7.44, 104.98) with n=52 of participants who had PHE intake over the 
recommendation.  The majority of the sample (74%, n= 57) were non-compliant with diet 
based on plasma PHE levels. 
 
Lab and Dietary Large Neutral Amino Acid outcomes  
 
Mean total LNAA plasma concentration was calculated with the sum of the individual 
plasma LNAA levels without tryptophan and phenylalanine (Table 5).5 Plasma 
concentration of LNAA did not differ between those with plasma PHE levels within the 
therapeutic range <360 μmol/L (compliant; 611.7 μmol/L [n=19]) vs. levels above the 
therapeutic range (non-compliant; 595.3 μmol/L [n=47]); p=0.613).  There was a 
negative correlation between the ratio of intact protein to medical food protein and 
plasma LNAA concentration for those who were compliant (r = -0.436, r=0.1), although 
the association was not statistically significant (p=0.08) (Figure 2). No correlation was 
found for patients who were non-compliant. (Figure 3).  Regression analysis predicted 
that only 15% of the variance in plasma LNAA concentration was attributed to the ratio 
of intact protein to medical food protein ratio (p=0.741), age (p=0.320), or gender 
(p=0.369).   
 
Discussion 
 The results of this study are useful for healthcare practitioners who provide 
energy and protein intake recommendations to people with PKU and also adds to the 
research literature on LNAA and their role in the treatment of PKU. Participants in our 
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population exceeded the recommended intakes of total energy and protein intakes, as 
shown in Table 3, suggesting that people with PKU are meeting their daily dietary 
requirements. Many participants also exceeded their recommended intake of PHE with a 
high percent of the sample being categorized as noncompliant based on their plasma PHE 
levels.  Therefore, we reject our null hypothesis that energy and protein intake would not 
meet recommended intake guidelines for those with PAH deficiency.  Plasma LNAA 
concentrations did not significantly differ by dietary compliance status based on Plasma 
PHE. However, we observed a negative correlation of borderline significance between 
the ratio of intact protein to medical food protein and plasma total LNAA concentration 
for the participants who had plasma PHE levels within the normal range. As a result of 
these observations, we fail to reject our null hypotheses that LNAA concentrations will 
not differ by dietary compliance in individuals with PAH deficiency or that the dietary 
source of LNAAs, as expressed by the ratio of intact protein to medical food protein, 
would not affect plasma concentrations of LNAAs in patients with PAH deficiency. 
 The energy and protein intake of our population were consistent with guidelines 
outlined in the Nutritional Management of Phenylketonuria. The guidelines state that 
people with PKU between the ages of 15 to 18 years should consume 0.84-0.87 g/kg of 
protein per day for females and males respectively.7 Our results show that participants 
reportedly consumed 1.108 g/kg of protein daily.  The energy guidelines state that those 
between ages 17-18 should consume 31- 37 kcal/kg and our population reportedly 
consumed 31.588 kcal/kg/day.  Rohde et al. (2014) examined EAA deficiency in people 
with PKU by evaluating the total protein intake in those who consumed medical food vs. 
those who did not.8 The researchers found no significant difference in the total protein 
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intake and no deficit in EAA intake. 8 These findings are consistent with the findings in 
the current study where a cohort of people with PKU met dietary protein intake 
recommendations. 
 Although research on the effect of LNAA intake and brain PHE levels is limited, 
previous studies have observed a lowering of brain PHE levels measured by Magnetic 
Resonance Spectroscopy with increased LNAA intake. 3 If confirmed, this may result in a 
change in medical nutrition therapy recommendations for people with PKU. 7 A study by 
Schindeler et al. (2007), found that blood isoleucine, threonine, tyrosine, valine, lysine, 
and histidine levels were all highest when subjects received LNAAs in their amino acid 
mixtures.9 This is consistent with the belief that LNAA intake has an impact on plasma 
LNAA concentrations. A study conducted by Concolino et al. (2017), examined the 
effectiveness of a medical formula containing LNAAs with lowering plasma PHE levels 
in those who had levels above 360 μmol/L.10 The researchers saw a decrease in blood 
PHE levels from 15.15 to 11.15 after consuming a high LNAA concentration formula for 
4 weeks (p=0.0333).10 These study results show that LNAAs can be useful in treating 
those with non-compliant PHE levels.  
 The results in the current study show that there is a negative correlation between 
the ratio of intact protein to medical food protein and large neutral amino concentration in 
those who had compliant plasma PHE levels. This suggests that those who consume more 
protein from medical food (resulting in a lower intact protein to medical food protein 
ratio) may have a higher plasma LNAA concentration.  Those who have compliant PHE 
levels are most likely consuming their medical formula. Most of LNAA consumption 
comes from the medical formula.  Therefore, those who are compliant have a lower intact 
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protein to medical formula protein ratio and higher plasma LNAA. LNAAs may have 
benefits that will reduce blood PHE levels and the concentration of PHE in the brain.   
 We do not yet know if the mean concentration of plasma LNAAs in our 
population differs from that of a similar age- and gender-matched cohort of people 
without PKU.  A study done by Shriver et al. (1985) studied plasma amino acid levels in 
normal, healthy adults.11 The following mean plasma LNAA levels (μmol/L) were found 
in the study population: threonine 145, isoleucine 64, leucine 133, methionine 24, 
tyrosine 64, valine 264, and histidine 94.11 Another study conducted by Lepage et al. 
(1997) studied proper methods of obtaining plasma amino acid levels in a healthy 
pediatric population. They found the following plasma LNAA concentrations (μmol/L) in 
16 year olds: threonine 104, isoleucine 47, leucine 101, methionine 20, tyrosine 46, 
valine 178, and histidine 77.12  Our cohort had LNAA plasma levels of threonine 109.79, 
isoleucine 48.26, leucine 99.67, methionine 19.35, tyrosine 49.29, valine 201.71, and 
histidine 72.38 which is very similar to the plasma LNAA levels observed in the pediatric 
population and just slightly lower than the levels observed in the healthy adult 
population. These values are included in the plasma LNAA levels in Table 5. The 
differing values in both of these populations is in the plasma PHE level. In the healthy 
pediatric population, plasma PHE was 47 μmol/L and in the healthy adults plasma PHE 
was 58 μmol/L compared to our cohort’s plasma PHE of 689.56 μmol/L.11,12  This proves 
that higher than normal intakes of LNAA need to be achieved in order to have the 
beneficial effects of PKU therapy. 
 The current study has some limitations. The majority of participants (74%) were 
non-compliant as evidenced by plasma PHE levels >360 μmol/L, minimizing the 
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compliant subgroup sample for our analysis. The homogeneity of our population being 
non-compliant hinders the ability to fully examine the correlation between source of 
dietary protein and plasma LNAA concentration.  Another limitation was that plasma 
tryptophan was not able to be calculated into the sum of plasma LNAA concentrations or 
for diet because the plasma values were not available for the Camp dataset. This may 
have affected the sum of the plasma LNAA concentration values and the significance of 
associations in the analysis. However, subgroup analysis where plasma tryptophan was 
available was still possible. Further, there were 10 subjects who were on other treatments 
(Kuvan and PegPal) that were not excluded from the sample. This could have altered the 
compliance as well as dietary protein intake of LNAA. Future research should include 
separation of the pediatric population from the adult population as well as comparing 
males to females to accurately report intakes compared to the Nutrition Management 
Guidelines for PKU as well as anthropometrics such as percentiles of weight, length, and 
weight/length. 
 The results of the current study show that people with PKU in the Emory 
University School of Medicine population are meeting the recommended intake of 
protein between their combined dietary protein and medical formula intakes. Although 
not statistically significant, a negative trend was observed between plasma total LNAA 
concentration and the intact protein to medical food protein ratio in patients compliant 
with the PHE prescription. This suggests that the ratio of intact dietary protein to protein 
coming from medical food, as reported by patient diet records, may influence the 
potential benefits of increased plasma LNAA levels in the treatment of PKU. Most the 
population (74%) were non-compliant with diet based on plasma PHE levels.  Future 
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studies are needed to determine the consequences of non-compliance by decreased intake 
of medical food protein or increased intake of intact protein on plasma LNAA 
concentration. 
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APPENDICES 
Table 3: Median Protein Intake and Energy Intake compared to Nutrition Management 
Guidelines for PKU. 
Macronutrient Intake Cohort Result (Mean age 
18.4 years + 10.9) 
 
Nutrition Management 
Guidelines for PKU.3 
Energy (kcal/kg) 31.588 31-37 
Protein (g/kg) 1.108 0.84-0.87 (female, male) 
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Table 4:  Reported Intake of Individual Amino Acids 
Amino Acid 
g/day 
 
Median Intake 
Interquartile Range   
(25%, 75%) 
Tryptophan 0.734 0.580, 1.144 
Threonine 2.627 2.112, 3.196 
Isoleucine 3.193 2.629, 4.286 
Leucine 5.546 4.764, 7.013 
Lysine 3.813 2.920, 5.111 
Methionine 1.170 0.909, 1.521 
Cysteine 0.760 0.599, 1.059 
Phenylalanine 0.607 0.410, 1.351 
Tyrosine 4.624 3.296, 6.063 
Valine 3.916 3.256, 5.004 
Arginine 3.598 3.018, 4.667 
Histidine 1.599 1.239, 1.899 
Alanine 3.373 2.696, 4.193 
Aspartic acid 3.306 1.943, 6.237 
Glutamine 6.847 2.906, 11.751 
Glycine 3.075 2.388, 3.869 
Proline 4.549 3.946, 5.659 
Serine 2.853 2.272, 3.562 
 
g - grams 
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Table 5: Plasma Levels of Individual Large Neutral Amino Acids 
Plasma Amino 
Acid 
(μmol/L) 
 
Mean + SD 
Shriver et al 
(1985)11 
Lepage et al 
(1997)12 
Tryptophan* 44.37 + 14.15 -- -- 
Threonine 109.79 + 42.54 145 104 
Isoleucine 48.26 + 12.75 64 47 
Leucine 99.67 + 23.58 133 101 
Methionine 19.35 + 5.06 24 20 
Tyrosine 49.29 + 18.50 64 46 
Valine 201.71 + 49.28 264 178 
Histidine  72.38 + 14.88 94 77 
 
SD – standard deviation, μmol/L – micromoles per liter 
*Plasma values available for only 39 participants in the current study 
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Figure 2.  Correlation between the Ratio of Intact Protein to Medical Food Protein 
(DIETMFRATIO) and Large Neutral Amino Acid (LNAA) Concentration in Participants who 
were Compliant with their Dietary Phenylalanine Recommendations. P= 0.08 
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Figure 3.  Correlation between the Ratio of Intact Protein to Medical Food Protein 
(DIETMFRATIO) and Large Neutral Amino Acid (LNAA) Concentration in Participants who 
were Non-Compliant with their Dietary Phenylalanine Recommendations. P=0.890 
 
 
 
 
 
 
  
 
